HOSPIRA BORTEZOMIB 3.5 mg powder for injection vial

Krajina: Austrália

Jazyk: angličtina

Zdroj: Department of Health (Therapeutic Goods Administration)

Aktívna zložka:

bortezomib, Quantity: 3.5 mg

Dostupné z:

Pfizer Australia Pty Ltd

Forma lieku:

Injection, powder for

Zloženie:

Excipient Ingredients: mannitol; nitrogen

Spôsob podávania:

Intravenous, Subcutaneous

Počet v balení:

1 vial/pack

Typ predpisu:

(S4) Prescription Only Medicine

Terapeutické indikácie:

Hospira Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. Hospira Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. Hospira Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. Hospira Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Prehľad produktov:

Visual Identification: White, to off white lyophilized powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stav Autorizácia:

Licence status A

Dátum Autorizácia:

2017-11-03